• 14 August 2019

    Deciphera reports positive results from INVICTUS study

    Deciphera Pharmaceuticals has announced positive findings from the Phase III INVICTUS clinical trial that evaluated ripretinib for the treatment of fourth-line and fourth-line plus gastrointestinal stromal tumours (GIST).

  • 12 August 2019

    Akari Therapeutics reports positive data for nomacopan

    Akari Therapeutics has reported positive results from an ongoing Phase II clinical trial assessing nomacopan for the treatment of an autoimmune inflammatory skin disease called bullous pemphigoid (BP).


Go Top